Polypharmacy is increasingly prevalent among U.S. adults, highlighting the need for targeted management, especially in older patients and those with cardiovascular or metabolic comorbidities.
Rising polypharmacy may heighten risks in older adults with heart disease or diabetes; leaves open optimal management strategies for prospective trials.
From 1999-2000 to 2017-2018, the prevalence of polypharmacy is continually increasing in U.S. adults. The polypharmacy was especially higher in the older, in patients with heart disease, or diabetes. The high prevalence urges the healthcare providers and health policymakers to manage polypharmacy among specific population groups.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: